This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
Blood Cancer Journal Open Access 14 August 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
Tefferi A . Classification, diagnosis and management of myeloproliferative disorders in the jak2v617f era. Hematology Am Soc Hematol Educ Program 2006, 240–245.
Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T . Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136.
Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466.
Spivak JL . Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272–4290.
Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 2006; 20: 1181–1183.
Thiele J, Kvasnicka HM . Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost 2006; 32: 219–230.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Conflict of interest/disclosure
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cassinat, B., Laguillier, C., Gardin, C. et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?. Leukemia 22, 452–453 (2008). https://doi.org/10.1038/sj.leu.2404908
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404908
This article is cited by
-
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study
Leukemia (2021)
-
Polycythemia Vera
Current Treatment Options in Oncology (2018)
-
The WHO diagnostic criteria for polycythemia vera—role of red cell mass versus hemoglobin/hematocrit level and morphology
Annals of Hematology (2018)
-
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
Blood Cancer Journal (2015)
-
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options
Annals of Hematology (2014)